Anti-Avian Influenza AFHA-1

Antibody Details

Product Details

Reactivity Species

Avian Influenza

Host Species

Goat

Product Concentration

0.5 mg/ml

Formulation

This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.

Storage and Handling

This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Next Day Ambient

RRID

AB_2828092

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Goat Anti-AFHA-1 recognizes AFHA-1. This polyclonal antibody was purified using affinity chromatography.

Background

Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. There was some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. HA interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues. Virus isolated from a human infected with the H5N1 strain in 1997 could bind to oligosaccharides from human as well as avian sources, indicating its species-jumping ability.

Antigen Details

Protein

AFHA-1

PubMed

AFHA-1

References & Citations

1. Thompson, W. W. et al. (2003) JAMA 289:179
2. Shortridge, K. F. et al. (1998) Virol. 252:331
3. Iwatsuki-Horimoto, K. et al.(2004) J. Gen. Virol. 85:1001

Technical Protocols